The EnSite X EP System is an advanced cardiac mapping system designed to optimise cardiac ablation procedures in arrythmia patients
Abbott headquarters. (Credit: Abbott.)
Abbott has secured Europe’s CE Mark approval and Australian regulatory approval for its new EnSite X EP System and is commercialising the system in Europe and Australia.
The health technology firm claimed that its EnSite X System is the only system to provide the option to navigate the cardiac anatomy in two different ways on a single platform.
The new cardiac mapping platform is designed based on Abbott’s electrophysiology portfolio and is intended for improving the delivery of ablation therapy for abnormal heart rhythms treatments.
For developing the system, the company has gathered feedback from physicians to meet current needs, and to address emerging opportunities during cardiac ablation procedures.
German Heart Centre electrophysiology head Isabel Deisenhofer said: “The high-density cardiac mapping capability this new system offers helps me to more quickly and accurately collect data and diagnose arrhythmias.
“The combination of the EnSite X System with the Advisor HD Grid mapping catheter, SE allows me to most effectively treat each patient’s unique needs without having to compromise our workflow in the EP lab.”
Abbott designed EnSite X EP System with advanced imaging capabilities
Cardiac mapping systems will help the electrophysiologists to create a map of the heart, to obtain a clear visualisation of the electrical signals associated with the cardiac rhythms.
With the created map of the heart, physicians are enabled to identify electrical disruptions, or portions of the heart with heart rhythm problems, and deploy cardiac ablation therapy.
Cardiac ablation is a minimally invasive procedure used for treating abnormal heartbeats by creating lesions, called ablations, in small areas of the heart tissue, causing arrhythmia.
The company said that its EnSite X System has been designed with advanced imaging capabilities that enable the creation of a 3D model of the patient’s cardiac anatomy in real-time.
Also, the device will enable physicians to clearly see the areas of heart requiring ablation treatment and select between impedance monitoring or electromagnetic technology to precisely locate the company’s sensor-enabled catheters during treatment.
IRCCS San Raffaele Hospital department of cardiac electrophysiology and arrhythmology head Paolo Della Bella said: “The new EnSite X System will fundamentally change how physicians approach longer, more complex ablation procedures as a result of its improved stability, faster mapping and better model visualization.
“In my first cases with the system it’s been apparent that the system is an important step forward in terms of technological capabilities and also truly helps improve my clinical analysis by protecting for patient movements.”